Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio

被引:58
作者
O'Hagan, A
Stevens, JW
Montmartin, J
机构
[1] Univ Sheffield, Stat Serv Unit, Sheffield S3 7RH, S Yorkshire, England
[2] Astra Charnwood, Loughborough, Leics, England
关键词
D O I
10.2165/00019053-200017040-00004
中图分类号
F [经济];
学科分类号
02 ;
摘要
The aim of this article is to consider Bayesian and frequentist inference methods for measures of incremental cost effectiveness in data obtained via a clinical trial. The most useful measure is the cost-effectiveness (C/E) acceptability curve. Recent publications on Bayesian estimation have assumed a normal posterior distribution, which ignores uncertainty in estimated variances; and suggest unnecessarily complicated methods of computation. We present a simple Bayesian computation for the C/E acceptability curve and a simple frequentist analogue. Our approach takes account of errors in estimated variances, resulting in calculations that are based on distributions rather than normal distributions. If inference is required about the C/E ratio, we argue that the standard frequentist procedures give unreliable or misleading inferences, and present instead a Bayesian interval.
引用
收藏
页码:339 / 349
页数:11
相关论文
共 33 条
  • [11] INITIAL EVALUATION OF HUMAN RECOMBINANT INTERLEUKIN-1 RECEPTOR ANTAGONIST IN THE TREATMENT OF SEPSIS SYNDROME - A RANDOMIZED, OPEN-LABEL, PLACEBO-CONTROLLED MULTICENTER TRIAL
    FISHER, CJ
    SLOTMAN, GJ
    OPAL, SM
    PRIBBLE, JP
    BONE, RC
    EMMANUEL, G
    NG, D
    BLOEDOW, DC
    CATALANO, MA
    FRIEDMAN, B
    MURE, A
    SHAPIRO, E
    [J]. CRITICAL CARE MEDICINE, 1994, 22 (01) : 12 - 21
  • [12] Heitjan DF, 1999, HEALTH ECON, V8, P191, DOI 10.1002/(SICI)1099-1050(199905)8:3<191::AID-HEC409>3.0.CO
  • [13] 2-R
  • [14] Problems with interval estimates of the incremental cost-effectiveness ratio
    Heitjan, DF
    Moskowitz, AJ
    Whang, W
    [J]. MEDICAL DECISION MAKING, 1999, 19 (01) : 9 - 15
  • [15] JONES DA, 1996, QUALITY LIFE PHARMAC, P1189
  • [16] Laska EM, 1997, HEALTH ECON, V6, P229, DOI 10.1002/(SICI)1099-1050(199705)6:3<229::AID-HEC268>3.0.CO
  • [17] 2-M
  • [18] Lee PM., 2012, BAYESIAN STAT INTRO
  • [19] LOTHGREN M, 1999, WORKING PAPER SERIES, V323
  • [20] The generalisability of pharmacoeconomic studies
    Mason, J
    [J]. PHARMACOECONOMICS, 1997, 11 (06) : 503 - 514